Article
Medicine, Research & Experimental
Jiaxin Chen, Yizheng Wu, Xin Luo, Dongai Jin, Wei Zhou, Zhenyu Ju, Di Wang, Qing Meng, Huijuan Wang, Xiaotian Fu, Jianbin Xu, Zhangfa Song
Summary: circRHOBTB3 is downregulated in colorectal cancer tissues and cell lines, overexpression of circRHOBTB3 suppresses tumor metastasis through the HuR/PTBP1 axis in CRC.
Article
Biochemistry & Molecular Biology
Xiaoshuai Ji, Zihao Liu, Jiajia Gao, Xin Bing, Dong He, Wenqing Liu, Yunda Wang, Yanbang Wei, Xianyong Yin, Fenglin Zhang, Min Han, Xiangdong Lu, Zixiao Wang, Qian Liu, Tao Xin
Summary: This study revealed the important role of long intergenic noncoding RNA in glioblastoma and its potential as a therapeutic target through modulating PTBP1-induced alternative splicing and m(6)A modification.
CELL DEATH AND DIFFERENTIATION
(2023)
Article
Oncology
Tengyang Ni, Zewen Chu, Li Tao, Yang Zhao, Miao Zhu, Yuanyuan Luo, Masataka Sunagawa, Haibo Wang, Yanqing Liu
Summary: PTBP1 is aberrantly highly expressed in gastric cancer and plays a crucial role in tumorigenesis and maintenance of stem-cell characteristics through stabilizing c-Myc protein. This study provides insights into the oncogenic role of PTBP1 and its involvement in gastric cancer progression.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Zewen Chu, Miao Zhu, Yuanyuan Luo, Yaqi Hu, Xinyi Feng, Haibo Wang, Masataka Sunagawa, Yanqing Liu
Summary: The study found that PTBP1 is highly expressed in gastric cancer patients and is correlated with poor prognosis. Downregulation of PTBP1 can inhibit the proliferation of gastric cancer cells and affect actin skeleton remodeling and proliferation signaling pathways. Therefore, PTBP1 may be a potential target for the treatment of gastric cancer.
CANCER CELL INTERNATIONAL
(2023)
Article
Biochemistry & Molecular Biology
Xinyi Fan, Zitong Zhao, Liying Ma, Xuanlin Huang, Qimin Zhan, Yongmei Song
Summary: This study reveals that the 5'UTR of Cyclin B1 mRNA contains an IRES, which initiates translation of Cyclin B1 and is further activated under cellular stress. PTBP1 promotes the IRES-mediated translation of Cyclin B1 by binding to its 5'UTR and enhances the malignancy of ESCC cells.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
(2022)
Article
Oncology
Hao Yang, Wensheng Sun, Tao Bi, Qi Wang, Wentao Wang, Youxin Xu, Zhiqian Liu, Jie Li
Summary: This study revealed that Polypyrimidine tract-binding protein 1 (PTBP1) mediates ferroptosis in liver cancer cells by regulating the translation of NCOA4, thereby reducing the sensitivity of liver cancer cells to ferroptosis after sorafenib treatment.
Article
Oncology
Cong Zhang, Huixia Wang, Qingwei Liu, Suli Dai, Guo Tian, Xintong Wei, Xiaoya Li, Lianmei Zhao, Baoen Shan
Summary: In this study, it was found that the expression of CCAT1 was significantly increased in the tissues and plasma exosomes of GC patients, as well as GC cell lines. Functional experiments showed that the knockdown of CCAT1 resulted in a substantial decrease in the proliferation, migration, and invasion of GC cells through decreasing the expression of glycolytic enzymes and glycolytic rate. Conversely, overexpression of CCAT1 exhibited contrasting effects.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Rajeswari Raguraman, Santny Shanmugarama, Meghna Mehta, Jo Elle Peterson, Yan D. Zhao, Anupama Munshi, Rajagopal Ramesh
Summary: Lung cancer is often diagnosed at an advanced stage with limited treatment options. RNA binding proteins, particularly Human antigen R (HuR), have been identified as key players in tumorigenesis, including lung cancer. This review explores the role of HuR in lung cancer progression and highlights various approaches, such as small molecule inhibitors, siRNAs, and shRNAs, for inhibiting HuR expression and function. These approaches have shown promising results in reducing tumor growth, invasion, migration, angiogenesis, and metastasis. Nanomedicine-based HuR targeting approaches using siRNA and shRNA delivery hold immense potential for enhancing cancer therapies in lung cancer patients.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Article
Oncology
Yasushi Mochizuki, Ryo Funayama, Matsuyuki Shirota, Yuna Kikukawa, Masahiro Ohira, Hideaki Karasawa, Minoru Kobayashi, Shinobu Ohnuma, Michiaki Unno, Keiko Nakayama
Summary: This study showed differential splicing of microexons in colorectal cancer, with 21 genes enriched in gene ontology terms related to cell adhesion and migration. RNA interference experiments identified RBFOX2 and PTBP1 as splicing regulators in CRC cells. Changes in microexon splicing patterns were associated with CRC metastasis, likely influenced by altered expression of RBFOX2 and PTBP1.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Cell Biology
Aoran Luo, Xiaoxiao Lan, Qiongzi Qiu, Qing Zhou, Jia Li, Mengting Wu, Pengyuan Liu, Honghe Zhang, Bingjian Lu, Yan Lu, Weiguo Lu
Summary: In this study, the researchers identified and explored the function and mechanism of long non-coding RNA surfactant associated 1 (SFTA1P) in cervical cancer. They found that SFTA1P is upregulated in cervical tumor tissues and its high expression is associated with poor prognosis. Knockdown of SFTA1P inhibited the proliferation, migration, and invasion of cervical cancer cells in vitro, as well as tumorigenesis and metastasis in vivo. Mechanistically, SFTA1P was shown to interact with polypyrimidine tract binding protein 1 (PTBP1) to regulate the stability of tropomyosin 4 (TPM4) mRNA, thereby resulting in malignant cell phenotypes. These findings provide a potential therapeutic strategy to target the SFTA1P-PTBP1-TPM4 axis in cervical cancer.
CELL DEATH & DISEASE
(2022)
Article
Medicine, Research & Experimental
Yixuan Cen, Tingjia Zhu, Yanan Zhang, Lu Zhao, Jiawei Zhu, Lingfang Wang, Junfen Xu, Tian Ding, Xing Xie, Xinyu Wang, Weiguo Lu
Summary: This study identified a downregulated circular RNA (hsa_circ_0005358) derived from the host gene Gli1 in cervical cancer tissues, which suppressed the migration and invasion abilities of cervical cancer cells by interacting with polypyrimidine tract-binding protein 1 (PTBP1), ultimately reducing cancer metastasis.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2022)
Article
Multidisciplinary Sciences
Hongyu Liu, Ran Duan, Xiaoyu He, Jincu Qi, Tianming Xing, Yahan Wu, Liping Zhou, Lingling Wang, Yujing Shao, Fulei Zhang, Huixing Zhou, Xingdong Gu, Bowen Lin, Yuanyuan Liu, Yan Wang, Yi Liu, Li Li, Dandan Liang, Yi-Han Chen
Summary: During heart development, the alternative splicing factor PTBP1 is involved in the regulation of ventricular chamber morphogenesis. The deletion of Ptbp1 reduces endothelial cell migration, disrupts cardiomyocyte proliferation, and ultimately leads to left ventricular noncompaction (LVNC). This study reveals the essential role of PTBP1 in ventricular chamber development.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, Research & Experimental
Hailing Liu, Tian Lan, Hui Li, Lin Xu, Xing Chen, Haotian Liao, Xiangzheng Chen, Jinpeng Du, Yunshi Cai, Jinju Wang, Xuefeng Li, Jiwei Huang, Kefei Yuan, Yong Zeng
Summary: Our study demonstrates that circDLC1 is downregulated in HCC tissues and is closely associated with a favorable prognosis. Overexpression of circDLC1 inhibits proliferation and motility of hepatoma cells, while silencing of circDLC1 has the opposite effect. Mechanistically, circDLC1 binds to RNA-binding protein HuR, reducing the interaction between HuR and MMP1 mRNA, leading to inhibition of MMP1 expression and ultimately suppressing HCC progression.
Review
Pharmacology & Pharmacy
Xiaoqing Wu, Liang Xu
Summary: RNA-binding proteins (RBPs) are crucial transcription factors that interact with specific cis elements in mRNA to regulate stability and translation. HuR, an overexpressed RBP in various human cancers, has been identified as a prognostic factor for poor clinical outcomes. HuR promotes tumorigenesis by interacting with oncogenic mRNAs involved in different cancer hallmarks and therapy resistance. Reducing HuR levels in cancer cells leads to tumor regression in mouse xenograft models. This review summarizes the roles of HuR in cancer and other diseases, the therapeutic potential of HuR inhibition, and the current status of drug discovery targeting HuR.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Article
Biochemistry & Molecular Biology
Andrea Ferrigno, Lucrezia Irene Maria Campagnoli, Annalisa Barbieri, Nicoletta Marchesi, Alessia Pascale, Anna Cleta Croce, Mariapia Vairetti, Laura Giuseppina Di Pasqua
Summary: The endogenous antioxidant defense, regulated by HuR, plays a crucial role in the pathogenesis of NAFLD. HuR controls the stability of MnSOD and HO-1 mRNA, two enzymes that protect liver cells from oxidative damage. In an NAFLD animal model, downregulation of HuR was observed along with reduced expression of MnSOD and HO-1, which correlated with oxidative stress and mitochondrial dysfunction. Targeting HuR could be a potential therapeutic strategy for preventing and treating NAFLD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
